You are here

  • Home
  • Archive
  • Volume 68, Issue 5
  • Smoking Termination Opportunity for inPatients (STOP): superiority of a course of varenicline tartrate plus counselling over counselling alone for smoking cessation: a 12-month randomised controlled trial for inpatients

Article Text

Article menu
Download PDFPDF
PostScript
Research letter
Smoking Termination Opportunity for inPatients (STOP): superiority of a course of varenicline tartrate plus counselling over counselling alone for smoking cessation: a 12-month randomised controlled trial for inpatients
  1. Brian James Smith1,
  2. Kristin Veronica Carson2,
  3. Malcolm Philip Brinn2,
  4. Nadina Ann Labiszewski2,
  5. Matthew J Peters3,
  6. Robert Fitridge4,
  7. Simon A Koblar5,
  8. Jim Jannes5,6,
  9. Antony J Veale1,
  10. Sharon J Goldsworthy7,
  11. John Litt8,
  12. David Edwards9,
  13. Adrian Jeffrey Esterman10
  1. 1Department of Respiratory Medicine, The Queen Elizabeth Hospital, Adelaide, South Australia, Australia
  2. 2Clinical Practice Unit, The Basil Hetzel Research Institute for Translational Health Research, The Queen Elizabeth Hospital, Woodville South, South Australia, Australia
  3. 3Department of Respiratory Medicine, Concord Repatriation General Hospital, Sydney, New South Wales, Australia
  4. 4University of Adelaide Department of Surgery, The Queen Elizabeth Hospital, Adelaide, South Australia, Australia
  5. 5Stroke Research Programme, University of Adelaide, Adelaide, South Australia, Australia
  6. 6Stroke Unit, The Queen Elizabeth Hospital, Adelaide, South Australia, Australia
  7. 7Department of Pharmacy, The Queen Elizabeth Hospital, Adelaide, South Australia, Australia
  8. 8Discipline of General Practice, Flinders University, Adelaide, South Australia, Australia
  9. 9Cancer Council South Australia, Adelaide, South Australia, Australia
  10. 10School of Nursing and Midwifery, The University of South Australia, Adelaide, South Australia, Australia
  1. Correspondence to Kristin Veronica Carson, Clinical Practice Unit, The Basil Hetzel Research Institute for Translational Health Research, The Queen Elizabeth Hospital, DX 465154, 28 Woodville Road, Woodville South, SA 5011, Australia; kristin.carson{at}health.sa.gov.au

Abstract

Rationale Smoking cessation interventions in outpatient settings have been demonstrated to be cost effective. Given this evidence, we aimed to evaluate the effectiveness of varenicline tartrate plus Quitline-counselling compared with Quitline-counselling alone when initiated in the inpatient setting.

Methods Adult patients (18–75 years) admitted with a smoking-related illness to three hospitals, were randomised to receive either 12-weeks of varenicline tartrate plus Quitline-counselling, (n=196) or Quitline-counselling alone, (n=196), with 12-months follow-up.

Results For the primary analysis population (intention-to-treat), the proportion of subjects who remained continuously abstinent were significantly greater in the varenicline plus counselling arm (31.1%, n=61) compared with counselling alone (21.4%, n=42; RR 1.45, 95% CI 1.03 to 2.03, p=0.03).

Conclusions The combined use of varenicline plus counselling when initiated in the inpatient setting has produced a sustained smoking cessation benefit at 12-months follow-up, indicating a successful opportunistic treatment for smokers admitted with smoking related illnesses.

Trial registration http://www.clinicaltrials.gov/ ClinicalTrials.gov identification number: NCT01141855.

  • Tobacco and the lung
  • Clinical Epidemiology

https://doi.org/10.1136/thoraxjnl-2012-202484

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    View Full Text